Novo Nordisk to Slash Wegovy and Ozempic Prices by 50% Starting January 2027

Novo Nordisk has clarified that its planned 50% price reduction for the list prices of Wegovy and Ozempic is scheduled to take effect in January 2027. Under this updated timeline, the monthly cost for these blockbuster GLP-1 medications will drop to approximately $675. This strategic move comes amid intensifying competition in the weight-loss drug market, particularly from Eli Lilly, and mounting political pressure in the U.S. to address high pharmaceutical costs. While the 2027 implementation date allows the company to maintain current profit margins in the near term, it signals a long-term commitment to expanding its total addressable market. Analysts suggest the announcement aims to mitigate future regulatory risks while forcing competitors to reconsider their pricing strategies. The shift is expected to significantly alter market dynamics once the lower pricing is officially implemented.